<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00857272</url>
  </required_header>
  <id_info>
    <org_study_id>F38-27</org_study_id>
    <nct_id>NCT00857272</nct_id>
  </id_info>
  <brief_title>F38-27: An Evaluation of 2 Different Bowel Cleansing Preparations in Adult Subjects</brief_title>
  <official_title>F38-27: An Evaluation of 2 Different Bowel Cleansing Preparations in Adult Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Braintree Laboratories</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Braintree Laboratories</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      To compare the safety and efficacy of 2 different bowel cleansing preparations prior to
      colonoscopy in adult subjects.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>February 2009</start_date>
  <primary_completion_date type="Actual">May 2009</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Efficacy: Percentage of Patients With Successful Preparations Based on a 4 Point Scale</measure>
    <time_frame>during colonoscopy</time_frame>
    <description>Cleansing was scored with a four point scale used in previous bowel cleansing studies where 4 = &quot;excellent&quot; (no more than small bits of adherent feces/fluid); 3 = &quot;good&quot; (small amounts of feces or fluid not interfering with the exam); 2 = &quot;fair&quot; (enough feces or fluid to prevent a completely reliable exam); 1 = &quot;poor&quot; (large amounts of fecal residue requiring additional cleansing). For the primary efficacy endpoint (preparation success), grades of 4 and 3 were considered a &quot;success&quot; and grades of 2 or 1 were considered a &quot;failure&quot;.</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">308</enrollment>
  <condition>Colonoscopy</condition>
  <arm_group>
    <arm_group_label>HalfLytely with 10mg bisacodyl</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Active control</description>
  </arm_group>
  <arm_group>
    <arm_group_label>HalfLytely with 5mg bisacodyl</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Investigational dose</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>PEG electrolyte lavage solution + bisacodyl - reformulation</intervention_name>
    <description>multi dose formulation (tablet/solution) for oral administration prior to colonoscopy</description>
    <arm_group_label>HalfLytely with 5mg bisacodyl</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>PEG electrolyte lavage solution + bisacodyl</intervention_name>
    <description>multi dose preparation (tablet/solution) for oral administration prior to colonoscopy</description>
    <arm_group_label>HalfLytely with 10mg bisacodyl</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Male or female outpatients who are undergoing colonoscopy for a routinely accepted
             indications:

          2. At least 18 years of age

          3. Otherwise in good health, as determined by physical exam and medical history

          4. If female, and of child-bearing potential, is using an acceptable form of birth
             control

          5. Negative urine pregnancy test at screening, if applicable

          6. In the Investigator's judgment, subject is mentally competent to provide informed
             consent to participate in the study

        Exclusion Criteria:

          1. Subjects with known or suspected ileus, gastrointestinal obstruction, gastric
             retention, bowel perforation, toxic colitis, or toxic megacolon

          2. Subjects with impaired consciousness that predisposes them to pulmonary aspiration

          3. Subjects who are undergoing colonoscopy for foreign body removal and decompression

          4. Subjects with pre-existing electrolyte disturbances, such as dehydration, or those
             secondary to the use of diuretics

          5. Subjects who are taking drugs that may affect electrolyte levels with the exception of
             routine diuretics

          6. Subjects with known clinically significant electrolyte abnormalities such as
             hypernatremia, hyperphosphatemia, hypokalemia, or hypocalcemia

          7. Subjects who are pregnant or lactating, or intending to become pregnant during the
             study

          8. Subjects of childbearing potential who refuse a pregnancy test

          9. Subjects who are allergic to any preparation components

         10. Subjects who, in the opinion of the Investigator, should not be included in the study
             for any reason, including inability to follow study procedures

         11. Subjects who have participated in an investigational clinical, surgical, drug, or
             device study within the past 30 days
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>John McGowan, MPH</last_name>
    <role>Study Director</role>
    <affiliation>Braintree Laboratories, Inc.</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Advanced Clinical Research Institute</name>
      <address>
        <city>Anaheim</city>
        <state>California</state>
        <zip>92801</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Advanced Clinical Research Institute</name>
      <address>
        <city>Orange</city>
        <state>California</state>
        <zip>92869</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medical Associates Research Group</name>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <zip>92123</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>United Medical Research</name>
      <address>
        <city>New Smyrna Beach</city>
        <state>Florida</state>
        <zip>32168</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Maryland Digestive Disease Research</name>
      <address>
        <city>Laurel</city>
        <state>Maryland</state>
        <zip>20707</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Franklin Gastroenterology</name>
      <address>
        <city>Franklin</city>
        <state>Tennessee</state>
        <zip>37067</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>September 2010</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 5, 2009</study_first_submitted>
  <study_first_submitted_qc>March 5, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 6, 2009</study_first_posted>
  <results_first_submitted>August 9, 2010</results_first_submitted>
  <results_first_submitted_qc>September 8, 2010</results_first_submitted_qc>
  <results_first_posted type="Estimate">September 28, 2010</results_first_posted>
  <disposition_first_submitted>May 3, 2010</disposition_first_submitted>
  <disposition_first_submitted_qc>May 3, 2010</disposition_first_submitted_qc>
  <disposition_first_posted type="Estimate">May 5, 2010</disposition_first_posted>
  <last_update_submitted>September 29, 2010</last_update_submitted>
  <last_update_submitted_qc>September 29, 2010</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 5, 2010</last_update_posted>
  <responsible_party>
    <name_title>John McGowan, Associate Director, Clinical Research</name_title>
    <organization>Braintree Laboratories, Inc.</organization>
  </responsible_party>
  <keyword>colonoscopy</keyword>
  <keyword>bowel preparation</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pharmaceutical Solutions</mesh_term>
    <mesh_term>Bisacodyl</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>HalfLytely With 5mg Bisacodyl</title>
          <description>Investigational dose</description>
        </group>
        <group group_id="P2">
          <title>HalfLytely With 10mg Bisacodyl</title>
          <description>Active Control</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="154">Includes 6 non-ITT patients that withdrew consent</participants>
                <participants group_id="P2" count="154">Includes 7 non-ITT patients that withdrew consent</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="145"/>
                <participants group_id="P2" count="145"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="9"/>
                <participants group_id="P2" count="9"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>HalfLytely With 5mg Bisacodyl</title>
          <description>Investigational dose</description>
        </group>
        <group group_id="B2">
          <title>HalfLytely With 10mg Bisacodyl</title>
          <description>Active Control</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="154"/>
            <count group_id="B2" value="154"/>
            <count group_id="B3" value="308"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="110"/>
                    <measurement group_id="B2" value="116"/>
                    <measurement group_id="B3" value="226"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="44"/>
                    <measurement group_id="B2" value="38"/>
                    <measurement group_id="B3" value="82"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="56.8" spread="12.1"/>
                    <measurement group_id="B2" value="55.0" spread="13.0"/>
                    <measurement group_id="B3" value="55.9" spread="12.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="78"/>
                    <measurement group_id="B2" value="90"/>
                    <measurement group_id="B3" value="168"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="76"/>
                    <measurement group_id="B2" value="64"/>
                    <measurement group_id="B3" value="140"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="154"/>
                    <measurement group_id="B2" value="154"/>
                    <measurement group_id="B3" value="308"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Efficacy: Percentage of Patients With Successful Preparations Based on a 4 Point Scale</title>
        <description>Cleansing was scored with a four point scale used in previous bowel cleansing studies where 4 = “excellent” (no more than small bits of adherent feces/fluid); 3 = “good” (small amounts of feces or fluid not interfering with the exam); 2 = “fair” (enough feces or fluid to prevent a completely reliable exam); 1 = “poor” (large amounts of fecal residue requiring additional cleansing). For the primary efficacy endpoint (preparation success), grades of 4 and 3 were considered a “success” and grades of 2 or 1 were considered a “failure”.</description>
        <time_frame>during colonoscopy</time_frame>
        <population>The analysis population consists of patients that were randomized and took any portion of the study preparation and who did not discontinue prior to colonoscopy due to a reason of safety or efficacy.</population>
        <group_list>
          <group group_id="O1">
            <title>HalfLytely With 5mg Bisacodyl</title>
            <description>Investigational dose</description>
          </group>
          <group group_id="O2">
            <title>HalfLytely With 10mg Bisacodyl</title>
            <description>Active Control</description>
          </group>
        </group_list>
        <measure>
          <title>Efficacy: Percentage of Patients With Successful Preparations Based on a 4 Point Scale</title>
          <description>Cleansing was scored with a four point scale used in previous bowel cleansing studies where 4 = “excellent” (no more than small bits of adherent feces/fluid); 3 = “good” (small amounts of feces or fluid not interfering with the exam); 2 = “fair” (enough feces or fluid to prevent a completely reliable exam); 1 = “poor” (large amounts of fecal residue requiring additional cleansing). For the primary efficacy endpoint (preparation success), grades of 4 and 3 were considered a “success” and grades of 2 or 1 were considered a “failure”.</description>
          <population>The analysis population consists of patients that were randomized and took any portion of the study preparation and who did not discontinue prior to colonoscopy due to a reason of safety or efficacy.</population>
          <units>percent of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="147"/>
                <count group_id="O2" value="146"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="77.6" lower_limit="69.9" upper_limit="84.0"/>
                    <measurement group_id="O2" value="80.1" lower_limit="72.7" upper_limit="86.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>The primary endpoint of preparation success was tested using a non-inferiority test based upon the difference D=P1-P2,
Null Hypothesis H0: P1-P2&lt;=D0 versus Alternative Hypothesis H1: P1-P2=D1&gt;D0,
Where P1 is the % of patients with successful preps in the HalfLytely 5mg group and P2 is the % of patients with successful preps in the HalfLytely 10mg group and D0 is the acceptable margin of equivalence equal to an absolute margin of 15%.</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Fifteen percent has been established as an acceptable non-inferiority margin for evaluation of investigational bowel preparations in previous studies of FDA approved preparations (e.g. NuLytely, MoviPrep).</non_inferiority_desc>
            <p_value>0.005</p_value>
            <method>Chi-squared</method>
            <param_type>Difference in success rates</param_type>
            <param_value>-2.5</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-11.9</ci_lower_limit>
            <ci_upper_limit>6.8</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>HalfLytely With 5mg Bisacodyl</title>
          <description>Investigational dose</description>
        </group>
        <group group_id="E2">
          <title>HalfLytely With 10mg Bisacodyl</title>
          <description>Active Control</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="154"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="154"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>urinary tract infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="154"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="154"/>
              </event>
              <event>
                <sub_title>urosepsis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="154"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="154"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>3</frequency_threshold>
        <default_vocab>MedDRA (Unspecified)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="117" subjects_at_risk="154"/>
                <counts group_id="E2" subjects_affected="129" subjects_at_risk="154"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal fullness</sub_title>
                <description>Patient completed questionnaire - expected preparation symptoms were rated as &quot;None&quot;, &quot;Mild&quot;, &quot;Bothersome&quot;, &quot;Distressing&quot; or &quot;Severely Distressing&quot;</description>
                <counts group_id="E1" subjects_affected="61" subjects_at_risk="154"/>
                <counts group_id="E2" subjects_affected="81" subjects_at_risk="154"/>
              </event>
              <event>
                <sub_title>Abdominal cramping</sub_title>
                <description>Patient completed questionnaire - expected preparation symptoms were rated as &quot;None&quot;, &quot;Mild&quot;, &quot;Bothersome&quot;, &quot;Distressing&quot; or &quot;Severely Distressing&quot;</description>
                <counts group_id="E1" subjects_affected="58" subjects_at_risk="154"/>
                <counts group_id="E2" subjects_affected="71" subjects_at_risk="154"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <description>Patient completed questionnaire - expected preparation symptoms were rated as &quot;None&quot;, &quot;Mild&quot;, &quot;Bothersome&quot;, &quot;Distressing&quot; or &quot;Severely Distressing&quot;</description>
                <counts group_id="E1" subjects_affected="53" subjects_at_risk="154"/>
                <counts group_id="E2" subjects_affected="65" subjects_at_risk="154"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" subjects_affected="15" subjects_at_risk="154"/>
                <counts group_id="E2" subjects_affected="10" subjects_at_risk="154"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Overall Discomfort</sub_title>
                <description>Patient completed questionnaire - expected preparation symptoms were rated as &quot;None&quot;, &quot;Mild&quot;, &quot;Bothersome&quot;, &quot;Distressing&quot; or &quot;Severely Distressing&quot;</description>
                <counts group_id="E1" subjects_affected="87" subjects_at_risk="154"/>
                <counts group_id="E2" subjects_affected="102" subjects_at_risk="154"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is more than 60 days but less than or equal to 360 days from the time submitted to the sponsor for review. The sponsor cannot extend the embargo.</restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>Total number of patients experiencing a non-serious adverse event is based on all adverse events, not just those events above the reporting threshold of 3%</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>John McGowan, Associate Director, Clinical Research</name_or_title>
      <organization>Braintree Laboratories, Inc.</organization>
      <phone>781-843-2202</phone>
      <email>jmcgowan@braintreelabs.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

